Navigation Links
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Date:9/15/2008

NDA for Omigard; the FDA may not agree with Cadence's interpretation of the outcomes of final analyses of data from the CLIRS trial; the performance of third parties on whom Cadence relies to conduct the CLIRS trial or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; clinical trial data for Omigard may demonstrate inadequate therapeutic efficacy, or the prevalence or severity of adverse side effects may be greater than anticipated; the company may experience delays in completing important pre-commercialization manufacturing development activities for Omigard, and may be required to perform additional pre-clinical or clinical testing prior to submitting, or obtaining approval of, an NDA for Omigard; the company may require substantial additional funding to complete the development programs for its product candidates, including Omigard, and, if approved, to successfully launch its product candidates, and it may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue

SVP & Chief Financial Officer

Cadence Pharmaceu
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
5. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
8. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
9. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
(Date:3/27/2015)... , March 27, 2015 Object recognition technology ... visually impaired and elderly. The VelaSense ® ... to lead more independent, productive and fulfilling lives. VelaSense ... will allow users to identify objects from a one ... as create customized object databases for personal use. ...
(Date:3/27/2015)... - Russell Williams , President of ... 2015-2016 Quebec Budget, noting the fiscal discipline and the ... However, the association is concerned about the decline of ... intent to strive for a balanced budget this year, ... Quebec,s economic development is encouraging," said Mr. ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... Inc. (OTC Bulletin Board: NEPH ), a ... therapeutic applications, infection control, and water purification, today announced ... previously announced rights offering to its existing stockholders was ... and Exchange Commission. Under the terms of ...
... 2011 Associates of Cape Cod, Inc., (ACC) ... DETECTION SYSTEM incorporating the enhanced Pyrochrome® chromogenic reagent ... tube reader. This system offers our customers diverse ... ACC,s enhanced Pyrochrome® is a versatile, quantitative reagent ...
Cached Medicine Technology:Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4New Chromogenic Endotoxin Detection System 2
(Date:3/27/2015)... According to a recently published report series by ... market in Europe is in decline due to decreasing ... Price decreases are being seen across the entire orthopedic ... total European trauma device market, continued pricing pressure overall ... after year. , “Such price drops are typical ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement ... on and analysis of the healthcare, regulatory and reimbursement ... in 2013 amounted to 316.1 million, having grown at ... 2008. The country’s increasingly elderly population and corresponding increase ... boost the growth of the pharmaceutical market, which was ...
(Date:3/27/2015)... 27, 2015 GrassrootsHealth, an international nonprofit ... Children (POC) NOW! vitamin D demonstration project April 7 ... South Carolina (MUSC), and will soon follow with a ... no cost to a minimum of 500 pregnant women ... these two service areas. The project will include patient ...
(Date:3/27/2015)... March 27, 2015 Trail mix is the ... workout, on weekend hikes and during the game! It’s portable, ... Natural is proud to introduce a new line of specialty ... Deliciously rich and flavorful selections packed with nutritious, 100% all ... fruit and grains that add protein and fiber to your ...
(Date:3/27/2015)... Since September 2014, the country singer has been traveling to ... in retirement for a period of 13 years. Many devoted ... touring, and concert events have been booking quickly in all ... for the two shows recently scheduled for May 8 and ... of discounted Garth Brooks tickets for sale. , The comeback ...
Breaking Medicine News(10 mins):Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... 2008 ended September 30, 2007, before the market ... host a conference call to,discuss these results on ... David Kaysen, President and Chief Executive Officer and ...
... Oriental,Bioengineering, Inc. (NYSE: AOB ), a leading ... in China, today,announced that the Company will attend ... present at the CIBC World Markets 18th Annual,Healthcare ... Waldorf-Astoria,Hotel in New York City. Management is currently ...
... - Providers Now Able to Submit Aetna Claims at ... MD On-Line, Inc., a leading,healthcare technology company focused on ... and payers, today,announced it has expanded its relationship with ... of October 1, 2007. Aetna is a leading,diversified health ...
... Cooper Benefits Helps Mid-Sized Companies Control Health Care ... world-renowned "father of,aerobics" Kenneth H. Cooper, M.D., M.P.H., ... in the company,s 37-year,history. Cooper Aerobics Enterprises purchased ... agent to create a new division, Cooper Benefits,LLC. ...
... N.J., Oct. 26 EP MedSystems,(Nasdaq: EPMD ) announces the following Webcast: ... 11/01/2007 @ 4:30 pm EST, Where: http://www.videonewswire.com/event.asp?id=43653 , ... on to the web at the ... EP MedSystems, 856-753-8533, ...
... Mattson Jack Group, Inc.,(MattsonJack) announces the release of ... to help clients make strategic,decisions based on an ... overlapping conditions. Comorbidity Database(TM) consists of,two modules: Comorbidity ... disorders, and Comorbidity Database(TM) -- Med 2.0, which ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2Health News:MD On-Line Expands Relationship with Aetna for Direct Claim Submission 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM) 2
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
200 L, Bulk, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. ...
Its generous filter placement, MicroPoint design, and reference marks at 10, 50, and 100 ul make this ART tip ideal for many 200 ul pipettors....
... tips, microfuge tubes and PCR tubes. ... RNase- and DNase-free. Tubes have a ... 120°C. Available in a variety of ... a low binding surface. PCR Tubes ...
Medicine Products: